Enlivex is a Nasdaq-listed company developing Allocetra, a clinical-stage immunotherapy for age-related knee osteoarthritis, and managing a treasury strategy with reserves linked to the Rain prediction markets protocol on Arbitrum. Its activities combine drug development with treasury exposure to protocol-related network activity.